161 related articles for article (PubMed ID: 16832340)
1. The 26S proteasome system degrades the ERM transcription factor and regulates its transcription-enhancing activity.
Baert JL; Beaudoin C; Monte D; Degerny C; Mauen S; de Launoit Y
Oncogene; 2007 Jan; 26(3):415-24. PubMed ID: 16832340
[TBL] [Abstract][Full Text] [Related]
2. The transcription of the intercellular adhesion molecule-1 is regulated by Ets transcription factors.
de Launoit Y; Audette M; Pelczar H; Plaza S; Baert JL
Oncogene; 1998 Apr; 16(16):2065-73. PubMed ID: 9572487
[TBL] [Abstract][Full Text] [Related]
3. The transcription factor Sox9 is degraded by the ubiquitin-proteasome system and stabilized by a mutation in a ubiquitin-target site.
Akiyama H; Kamitani T; Yang X; Kandyil R; Bridgewater LC; Fellous M; Mori-Akiyama Y; de Crombrugghe B
Matrix Biol; 2005 Jan; 23(8):499-505. PubMed ID: 15694126
[TBL] [Abstract][Full Text] [Related]
4. PIASy controls ubiquitination-dependent proteasomal degradation of Ets-1.
Nishida T; Terashima M; Fukami K; Yamada Y
Biochem J; 2007 Aug; 405(3):481-8. PubMed ID: 17456046
[TBL] [Abstract][Full Text] [Related]
5. SUMO modification of the Ets-related transcription factor ERM inhibits its transcriptional activity.
Degerny C; Monte D; Beaudoin C; Jaffray E; Portois L; Hay RT; de Launoit Y; Baert JL
J Biol Chem; 2005 Jul; 280(26):24330-8. PubMed ID: 15857832
[TBL] [Abstract][Full Text] [Related]
6. MYO18B interacts with the proteasomal subunit Sug1 and is degraded by the ubiquitin-proteasome pathway.
Inoue T; Kon T; Ajima R; Ohkura R; Tani M; Yokota J; Sutoh K
Biochem Biophys Res Commun; 2006 Apr; 342(3):829-34. PubMed ID: 16499872
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells.
Chen C; Sun X; Ran Q; Wilkinson KD; Murphy TJ; Simons JW; Dong JT
Oncogene; 2005 May; 24(20):3319-27. PubMed ID: 15735697
[TBL] [Abstract][Full Text] [Related]
8. Linking the ubiquitin-proteasome pathway to chromatin remodeling/modification by nuclear receptors.
Kinyamu HK; Chen J; Archer TK
J Mol Endocrinol; 2005 Apr; 34(2):281-97. PubMed ID: 15821097
[TBL] [Abstract][Full Text] [Related]
9. Rush hour at the promoter: how the ubiquitin-proteasome pathway polices the traffic flow of nuclear receptor-dependent transcription.
Dennis AP; O'Malley BW
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):139-51. PubMed ID: 15860256
[TBL] [Abstract][Full Text] [Related]
10. A putative stimulatory role for activator turnover in gene expression.
Lipford JR; Smith GT; Chi Y; Deshaies RJ
Nature; 2005 Nov; 438(7064):113-6. PubMed ID: 16267558
[TBL] [Abstract][Full Text] [Related]
11. A conditional version of the Ets transcription factor Erm by fusion to the ligand binding domain of the oestrogen receptor.
Pelczar H; Albagli O; Chotteau-Lelievre A; Damour I; de Launoit Y
Biochem Biophys Res Commun; 1997 Oct; 239(1):252-6. PubMed ID: 9345304
[TBL] [Abstract][Full Text] [Related]
12. Constitutive ubiquitination and degradation of c-myb by the 26S proteasome during proliferation and differentiation of myeloid cells.
Feiková S; Wolff L; Bies J
Neoplasma; 2000; 47(4):212-8. PubMed ID: 11043824
[TBL] [Abstract][Full Text] [Related]
13. A novel N-terminal hydrophobic motif mediates constitutive degradation of serum- and glucocorticoid-induced kinase-1 by the ubiquitin-proteasome pathway.
Bogusz AM; Brickley DR; Pew T; Conzen SD
FEBS J; 2006 Jul; 273(13):2913-28. PubMed ID: 16817852
[TBL] [Abstract][Full Text] [Related]
14. Expression of the Ets transcription factor Erm is regulated through a conventional PKC signaling pathway in the Molt4 lymphoblastic cell line.
T'sas F; Brenner C; Mauen S; Putmans P; Monté D; Van Lint C; Moser M; Baert JL; de Launoit Y
FEBS Lett; 2005 Jan; 579(1):66-70. PubMed ID: 15620692
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression and potential roles of human Sp5, a member of Sp transcription factor family, in human cancers.
Chen Y; Guo Y; Ge X; Itoh H; Watanabe A; Fujiwara T; Kodama T; Aburatani H
Biochem Biophys Res Commun; 2006 Feb; 340(3):758-66. PubMed ID: 16380080
[TBL] [Abstract][Full Text] [Related]
16. A ubiquitin-interacting motif protects polyubiquitinated Met4 from degradation by the 26S proteasome.
Flick K; Raasi S; Zhang H; Yen JL; Kaiser P
Nat Cell Biol; 2006 May; 8(5):509-15. PubMed ID: 16604062
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic activation of c-Myb by carboxyl-terminal truncation leads to decreased proteolysis by the ubiquitin-26S proteasome pathway.
Bies J; Wolff L
Oncogene; 1997 Jan; 14(2):203-12. PubMed ID: 9010222
[TBL] [Abstract][Full Text] [Related]
18. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.
Chu I; Arnaout A; Loiseau S; Sun J; Seth A; McMahon C; Chun K; Hennessy B; Mills GB; Nawaz Z; Slingerland JM
J Clin Invest; 2007 Aug; 117(8):2205-15. PubMed ID: 17627304
[TBL] [Abstract][Full Text] [Related]
19. [Mapping of Rpn4p regions responsible for transcriptional activation of proteasome genes].
Karpov DS; Tiutiaeva VV; Beresten' SF; Karpov VL
Mol Biol (Mosk); 2008; 42(3):526-32. PubMed ID: 18702312
[TBL] [Abstract][Full Text] [Related]
20. [Ubiquitins, proteasomes, sumoylation and therapeutic application today and in future for cancer and other diseases. I. Ubiquitin-proteasome system and the transcription factor NF-kappaB].
Fuchs O; Neuwirtová R
Vnitr Lek; 2006 Apr; 52(4):371-8. PubMed ID: 16755993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
